Community Practice Connections™: 13th Annual New York Lung Cancers Symposium

Community Practice Connections™: 13th Annual New York Lung Cancers Symposium is organized by Physicians' Education Resource, LLC (PER) and will be held from Jan 31, 2019 - Jan 31, 2020.

Target Audience:
This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, and pulmonologists involved in the treatment and management of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung cancer may also participate.

Accreditation:
?Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Activity Overview:
Community Practice Connections™: 13th Annual New York Lung Cancers Symposium consists of a series of interactive clinical vignettes, short video interviews of leading experts in lung cancer, and brief summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting.

Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Apply testing strategies to optimize tumor characterization and inform clinical decision-making for the management of patients with lung cancers
• Integrate prognostic and biomarker findings to inform personalized treatment planning and sequencing for patients with non-small cell lung cancer (NSCLC) and small cell lung cancer
• Evaluate recent and emerging evidence concerning single-agent and combination immunotherapeutic approaches to managing lung cancers
• Explain current and emerging oncogene-driven NSCLC subtypes in the context of optimizing therapeutic sequencing for multiple lines of therapy
• Determine optimized strategies for patients without mutations, including the role of chemotherapies and antiangiogenic strategies in these settings
• Assess proactive strategies to plan for and mitigate the impact of treatment-related toxicities in the care of patients with lung cancers.